A Multicenter, International, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel-group, 2-arm, Phase 3 Study to Compare the Efficacy and Safety of the Oral FXIa Inhibitor Asundexian (BAY 2433334) With Apixaban for the Prevention of Stroke or Systemic Embolism in Male and Female Participants Aged 18 Years and Older With Atrial Fibrillation at Risk for Stroke
A Multicenter, International, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel-group, 2-arm, Phase 3 Study to Compare the Efficacy and Safety of the Oral FXIa Inhibitor Asundexian (BAY 2433334) With Apixaban for the Prevention of Stroke or Systemic Embolism in Male and Female Participants Aged 18 Years and Older With Atrial Fibrillation at Risk for Stroke
Researchers are looking for a better way to treat people with atrial fibrillation (AF) and prevent stroke or systemic embolism (blood clots travelling through the blood stream to plug another vessel).
Atrial fibrillation is a condition of having irregular and often rapid heartbeat. It can lead to the formation of blood clots in the heart which can travel through the blood stream to plug another vessel, and like this lead to serious and life-threatening conditions, such as a stroke. A stroke occurs because the brain tissue beyond the blockage no longer receives nutrients and oxygen so that brain cells die. As strokes arising from atrial fibrillation can involve extensive areas of the brain, it is important to prevent them.
Blood clots are formed in a process known as coagulation. Medications are already available to prevent the formation of blood clots. When taken by mouth (orally), they are known as oral anticoagulants (OACs) including apixaban. OACs decrease the risk of the above-mentioned serious and life-threatening conditions. The main side effect of OACs is an increase of the risk of bleeding.
The study treatment asundexian is a new type of anticoagulant currently under development to provide further treatment options. Asundexian aims to further improve the standard of care with regard to the risk of bleeding.
The main purpose of this study is to collect more data about how well asundexian works to prevent stroke and systemic embolism and how safe it is compared to apixaban in people with atrial fibrillation and at high risk for stroke.
To see how well the study treatment asundexian works researchers compare:
To see how safe asundexian is, the researchers will compare how often major bleedings occur after taking the study treatments asundexian and apixaban, respectively. Major bleedings are bleedings that have a serious or even life-threatening impact on a person's health.
The study participants will be randomly (by chance) assigned to 1 of 2 treatment groups, A and B. Dependent on the treatment group, the participants will either take the study treatment asundexian by mouth once a day or apixaban by mouth twice a day for approximately 9 - 33 months.
Each participant will be in the study for approximately 9 - 34 months. There will be visits to the study site every 3 to 6 months and up to 7 phone calls. Those participants who do not want or are unable to have visits to the study site may join the study remotely in selected locations. The location name contains the abbreviation - DCT in such cases.
During the study, the study team will:
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
Inclusion Criteria:
18 years of age or older
The patient willing and able to understand the Patient information Sheet and provide written informed consent
Atrial fibrillation with an indication for indefinite treatment with an oral anticoagulant
CHA2DS2-VASc score ≥ 3 if male or ≥ 4 if female, OR CHA2DS2-VASc score of 2 if male or 3 if female and at least one of the following enrichment criteria:
Exclusion Criteria:
Mechanical heart valve prosthesis
Moderate-to-severe mitral stenosis at the time of study inclusion.
Atrial fibrillation only due to reversible cause.
Participants after successful ablation therapy without documented recurrent AF or participants after left atrial appendage occlusion / exclusion or plan for ablation or Left atrial appendage (LAA) occlusion / exclusion within the next 6 months.
Recent ischemic stroke (within 7 days prior to randomization).
Active non-trivial bleeding; known chronic bleeding disorder ; history of non-traumatic intracranial hemorrhage.
Known significant liver disease or known hepatic insufficiency classified as Child-Pugh B or C at randomization.
Estimated glomerular filtration rate (eGFR) < 25 mL/min/1.73 m2 within 14 days prior to randomization or on dialysis or expected to be started on dialysis within the next 12 months starting from randomization.
Major surgery during the last 30 days prior to randomization.
Known allergy, intolerance or hypersensitivity to either of the study interventions.
Any contraindication for the use of an anticoagulant or listed in the local labelling for apixaban.
Requirement for chronic anticoagulation for a different indication than AF, e.g. mechanical heart valve or left ventricular cardiac thrombus (atrial thrombus is allowed), or dual antiplatelet therapy (single agent therapy is allowed).
Treatment with Vitamin K antagonist (VKA) in the 10 days prior to randomization.
Concomitant use of or anticipated need for:
Previous (within 30 days or 5 half-lives of the investigational drug, whichever is longer) or concomitant participation in another clinical study with investigational medicinal product(s) or device(s). Registries and observational studies are allowed.
Known current alcohol and / or illicit drug abuse.
Close affiliation with the investigational site.
Any other history, condition or therapy, or uncontrolled intercurrent illness which would make the participant unsuitable for the study vulnerable or life expectancy < 12 months.
Los Angeles, California 90073-1003, United States
Santa Barbara, California 93102, United States
Norwalk, Connecticut 06851, United States
Boynton Beach, Florida 33472, United States
Gainesville, Florida 32608, United States
Inverness, Florida 34452, United States
Palm Beach Gardens, Florida 33410, United States
Saint Augustine, Florida 32081, United States
Sarasota, Florida 34239, United States
Wellington, Florida 33449, United States
West Palm Beach, Florida 33407-2495, United States
Meridian, Idaho 83642, United States
Elkhart, Indiana 46514, United States
Hammond, Indiana 46320, United States
Scarborough, Maine 04039, United States
Baltimore, Maryland 21215, United States
Baltimore, Maryland 21229, United States
Ft. Washington, Maryland 20744, United States
Bay City, Michigan 48708, United States
Lansing, Michigan 48912, United States
Minneapolis, Minnesota 55417, United States
New York, New York 10001, United States
Chapel Hill, North Carolina 27514, United States
Durham, North Carolina 27710-4000, United States
Erie, Pennsylvania 16507, United States
Providence, Rhode Island 02906, United States
Tomball, Texas 77375, United States
Tyler, Texas 75702, United States
Port Orchard, Washington 98366, United States
Bahía Blanca, Buenos Aires 8000, Argentina
General Arenales, Buenos Aires C1061AAS, Argentina
Lanus, Buenos Aires B1824, Argentina
Mar del Plata, Buenos Aires B7600FZ0, Argentina
San Nicolás de los Arroyos, Buenos Aires B2900DMH, Argentina
Temperley, Buenos Aires B1834GUK, Argentina
Zárate, Buenos Aires B2800DGH, Argentina
Buenos Aires, Ciudad Auton. de Buenos Aires C1056ABJ, Argentina
CABA, Ciudad Auton. de Buenos Aires C1018DES, Argentina
Villa Luro, Ciudad Auton. de Buenos Aires C1440CFD, Argentina
Rosario, Santa Fe Province S2000DEJ, Argentina
San Miguel de Tucumán, Tucumán Province T4000ICL, Argentina
Corrientes, 3400, Argentina
Blacktownn, New South Wales 2148, Australia
Liverpool, New South Wales 2170, Australia
Taringa QLD, Queensland 4068, Australia
Kortrijk, West-Vlaanderen 8500, Belgium
Bruxelles - Brussel, 1200, Belgium
Goiânia, Goiás 74605-020, Brazil
Belo Horizonte, Minas Gerais 30150-240, Brazil
Poços de Caldas, Minas Gerais 37706-106, Brazil
Curitiba, Paraná 80045-170, Brazil
Paraná, Paraná 83430-000, Brazil
Porto Alegre, Rio Grande do Sul 90020-090, Brazil
Porto Alegre, Rio Grande do Sul 90035-903, Brazil
Porto Alegre, Rio Grande do Sul 91350-200, Brazil
Campinas, São Paulo 13060-080, Brazil
Santo André, São Paulo 09030-010, Brazil
São Paulo, São Paulo 01221-020, Brazil
São Paulo, São Paulo 04012-909, Brazil
Burgas, 8000, Bulgaria
Plovdiv, 4004, Bulgaria
Shumen, 9700, Bulgaria
Silistra, 7500, Bulgaria
Sofia, 1233, Bulgaria
Sofia, 1309, Bulgaria
Sofia, 1527, Bulgaria
Sofia, 1606, Bulgaria
Sofia, 1618, Bulgaria
Stara Zagora, 6000, Bulgaria
Veliko Tarnovo, 5000, Bulgaria
London, Ontario N6A5A5, Canada
Toronto, Ontario M5S 1B2, Canada
JiangSu, Jiangsu 212001, China
Yangzhou, Jiangsu 225012, China
Taian, Shandong 271099, China
Ostrava - Poruba, Moravian-Silesian Region 708 68, Czechia
Århus N, 8200, Denmark
Frederiksberg, 2000, Denmark
Hilleroed, 3400, Denmark
Svendborg, 5700, Denmark
Heidelberg, Baden-Wurttemberg 69120, Germany
Hagen, North Rhine-Westphalia 58135, Germany
Remscheid, North Rhine-Westphalia 42859, Germany
Warendorf, North Rhine-Westphalia 48231, Germany
Mainz, Rhineland-Palatinate 55101, Germany
Jerusalem, 9103102, Israel
Jerusalem, 9112001, Israel
Lower Galilee, 15208, Israel
Petah Tikva, 4941492, Israel
Tel Aviv, 6423906, Israel
Bologna, Emilia-Romagna 40133, Italy
Toyota, Aichi-ken 470-0396, Japan
Onga-gun, Fukuoka 811-4342, Japan
Tateyashiki, Mizumakimachi, on, Fukuoka 807-0051, Japan
Shirakawa, Fukushima 105-0021, Japan
Aki-gun, Hiroshima 735-8585, Japan
Higashiibaraki, Ibaraki 311-3193, Japan
Hakusan, Ishikawa-ken 924-8588, Japan
Kahoku-gun, Ishikawa-ken 920-0293, Japan
Kanazawa, Ishikawa-ken 920-8650, Japan
Miura-gun, Kanagawa 240-0116, Japan
Suzuka-shi, Mie-ken 513-8630, Japan
Sendai, Miyagi 983-8512, Japan
Kitaazumi-gun, Nagano 399-8695, Japan
Nakano, Nagano 383-8505, Japan
Umeda Kita-Ku, Osaka-shi, Osaka 5320001, Japan
Shimotsuga-gun, Tochigi 321-0293, Japan
Bunkyo-ku, Tokyo 113-8519, Japan
Chuo-ku, Tokyo 103-0027, Japan
Itabashi-ku, Tokyo 173-8610, Japan
Meguro-ku, Tokyo 152-8902, Japan
Minato-ku, Tokyo 108-0073, Japan
Shinjuku-ku, Tokyo 169-0073, Japan
Suginami-ku, Tokyo 168-0065, Japan
Okayama, 7008557, Japan
Okayama, 7028055, Japan
Kelantan, 15200, Malaysia
Kelantan, TBC, Malaysia
Sarawak, 93400, Malaysia
Sarawak, 94300, Malaysia
Enschede, 7611 JH, Netherlands
Nordbyhagen, 1478, Norway
Lowicz, 99-400, Poland
Guimaraes, Braga, Braga District 4835-044, Portugal
Covilha, Castelo Branco District 6200-251, Portugal
Lisbon, Lisbon District 1500-650, Portugal
Lisbon, Lisbon District 1649-035, Portugal
Vila Franca de Xira, Lisbon District 2600-009, Portugal
Matosinhos Municipality, Porto District 4464-513, Portugal
Coimbra, 3004-561, Portugal
Guilhufe, 4564-007, Portugal
Porto, 4200-319, Portugal
Porto, 4434-502, Portugal
Vila Real, 5000-508, Portugal
Cluj-Napoca, Dolj 400015, Romania
Uijeongbu-si, Gyeonggi-do, Gyeonggido 11765, South Korea
Seoul, Seoul Teugbyeolsi 03312, South Korea
Ferrol, A Coruña 15405, Spain
Santiago de Compostela, A Coruña 15706, Spain
L'Hospitalet de Llobregat, Barcelona 08907, Spain
Sanlúcar de Barrameda, Cádiz 11540, Spain
Villamartín, Cádiz 11650, Spain
Madrid, Madrid [es-m] 28006, Spain
Oviedo, Principality of Asturias 33006, Spain
Alicante, 03010, Spain
Barcelona, 08035, Spain
Seville, 41013, Spain
Taipei, Taipei 111, Taiwan
Taipei, Taipei 116, Taiwan
Torbay, Devon TQ2 7AA, United Kingdom